Windtree Therapeutics, Inc. Announces Reverse Stock Split. https://bit.ly/3QmN2vN
Windtree Therapeutics, Inc.
制药业
Warrington，PA 1,872 位关注者
Delivering the Realization of Hope for a Life less Impacted by Disease
关于我们
Windtree Therapeutics, Inc. (NasdaqCM: WINT) is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree’s portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. For more company information, please visit https://windtreetx.com/.
- 网站
-
http://www.windtreetx.com/
Windtree Therapeutics, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Warrington，PA
- 类型
- 上市公司
- 创立
- 1992
- 领域
- Respiratory Therapies、Aerosol Drug Delivery、Surfactant Technology、Cardiology、Acute Heart Failure、Oncology、Medical Device、Research and Development、Manufacturing、biotechnology、pharmaceutical、neonatology和hypertension
地点
-
主要
获取路线
2600 Kelly Rd.
Suite 100
US，PA，Warrington，18976
Windtree Therapeutics, Inc.员工
动态
-
Dr. Steve Simonson, CMO and SVP of Windtree, discusses the late-breaking clinical science abstract on istaroxime presented at the Technology and Heart Failure Therapeutics Meeting, emphasizing its potential in treating cardiogenic shock. Learn more: https://bit.ly/4jWKaTT #THT2025
-
Matteo Pagnesi, MD, PhD a cardiologist from Spedali Civili di Brescia, Italy gave the presentation entitled, “Hemodynamic Effects of Intravenous Istaroxime in Patients With SCAI Stage B Cardiogenic Shock: Insights From the SEISMiC Trial" at #THT2025. Learn more: https://bit.ly/4jWKaTT
-
A late-breaking clinical science abstract presentation on istaroxime featuring the positive Phase 2b SEISMiC study was given at the Technology and Heart Failure Therapeutics Meeting in Boston, MA on February 11. Learn more: https://bit.ly/4jWKaTT #THT2025
-
Windtree's aPKCi inhibitor platform includes two formulations (topical and oral) that have been in development in partnership with Cancer Research UK and top academic research centers. https://bit.ly/4am1I7S $WINT
-
CEO, Jed Latkin, discusses the issuance of a new patent for Windtree's oncology aPKCi inhibitor pipeline, emphasizing its role in advancing the company's development strategy. Discover more: https://bit.ly/4am1I7S $WINT
-
Windtree's aPKCi inhibitor platform is a novel, potential high-potency, specific, first in class drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. Learn more: https://bit.ly/4am1I7S
-
Windtree announced the issuance of a patent in Japan for “Inhibitors of atypical protein kinase C (aPKCi) and their use in treating hedgehog pathway-dependent cancers.” Find details: https://bit.ly/4am1I7S
-
Windtree CEO, Jed Latkin, welcomes Leanne Kelly to the company's board of directors. Learn more about Ms. Kelly here: https://bit.ly/426IkJO
-
Windtree is pleased to announce the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and joins the Board as an independent director and chair of the audit committee. More info: https://bit.ly/426IkJO